No data pointing to CYP-interaction. Clinical experience of non-porphyrinogenicity.

Quinazoline derivative

Antihypertensive quinazoline derivative, also used in prostatic hyperplasia. Dose 4-8 mg/d.

Extensively metabolised in the liver, primarily excreted in faeces as metabolites and only a small amount of unchanged drug. Oxidative metabolism occurs, but data on CYP450 metabolism are lacking.

Thunell, patient reports (n=5): tolerated. Andersson, patient reports(n=11): tolerated.

Doxazosin was used uneventfully in 60 year old AIP woman (Gorchein, 1997). Also used uneventfully in AIP man of 55 (Turton-Weeks, 2001).

Uneventful use reported in 19 patients with acute porphyria.